<DOC>
	<DOCNO>NCT02177110</DOCNO>
	<brief_summary>This exploratory prospective translational multicentre study . Melanoma 5th common cancer diagnose Ireland incidence among woman men European average . Following treatment elimination cancer cell ultimately occur activation apoptotic cell death pathway . The SYS-ACT approach build combination mathematical system model , quantitative biochemistry cell biology , specifically predict drug responsiveness melanoma cell line various apoptosis-inducing treatment . The investigator propose validate SYS-ACT approach application translational system medicine study .</brief_summary>
	<brief_title>A Translational Systems Medicine Approach Provide Predictive Capacity Therapy Response Advanced Metastatic Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Patients â‰¥ 18 year age . 2 . Patient must able give sign informed consent . 3 . Patients present advanced metastatic ( stage III/IV ) malignant melanoma skin . 4 . Patients plan receive either : Adjuvant treatment 1st line treatment metastatic disease 2nd line treatment metastatic disease 5 . Patients prior adjuvant treatment allow . 6 . Patients receive planned standard treatment one following : Chemotherapy regimens contain DTIC , TMZ and/or cisplatin Immunotherapy ( example ipilimumab and/or antiPDL1/PD1 therapy ) BRAF and/or MEK inhibitor 7 . Patients FFPE fresh frozen tissue available ( mandatory ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>advanced melanoma</keyword>
	<keyword>metastatic melanoma</keyword>
	<keyword>fresh frozen tissue</keyword>
	<keyword>FFPE tissue</keyword>
</DOC>